Correction: *Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model*

Loymans RJ, Honkoop PJ, Termeer EH, *et al*. Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. *Thorax* 2016;71:838–46. doi: 10.1136/thoraxjnl-2015-208138

Data on the external validation are incorrect; corrections in **bold**.

Page 838 (Abstract): External validation yielded AUROCs of **0.69** (95% CI **0.63** to **0.75**; **0.63** to **0.75** and **0.63** to **0.75**) for the three models, respectively; calibration was best for the spirometry model.

Page 840: The three models were validated externally in the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) data set (n=317), (details in online supplementary appendix I).

Page 841: U-BIOPRED participants had poor asthma symptom control and low lung function; **66.6**% had **a severe** asthma exacerbation in the previous year (see online supplementary table A5 appendix II). The exacerbation risk was higher than in the derivation data set, with **54.9**% experiencing a severe exacerbation during 1 year follow-up. Discriminative properties of the models were lower in the external validation set (AUROC **0.69** (95% CI **0.63** to **0.75**), **0.69** (95% CI **0.63** to **0.75**) and **0.69** (95% CI **0.63** to **0.75**)) for the three models, respectively (figure 1B).

Page 483: the U-BIOPRED population largely consists of patients with severe asthma and this is reflected in an annual exacerbation risk of about **55**% against 13% in the ACCURATE cohort.

Page 844: Predictive properties remained **essentially** intact on external validation (AUROC **0.69**) in a population with more severe asthma and a higher (**55**%) exacerbation risk.

BMJ

Corrected figure 2 panel 1-3B

Check for updates